# Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids

Source: https://onco.cc/trials/nct06227065/  
OnCo record `nct06227065` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Patient-derived organoids in Non-muscle-invasive bladder cancer, run by Hospital Centre Biel/Bienne, not yet recruiting.

## Summary

Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids is a phase 2 interventional study registered as NCT06227065 by Hospital Centre Biel/Bienne, with 28 participants planned, started 2026-12-01 and due to reach its primary completion in 2030-11-30. Interventions recorded: Epirubicin, Mitomycin, Gemcitabine, Docetaxel. Conditions recorded: Bladder Cancer, Non-muscle Invasive Bladder Cancer, Low Grade.

Linked to the technology Patient-derived organoids because the registry's title names it ("patient derived organoids") and Non-muscle-invasive bladder cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06227065
- Phase: 2
- Setting: POLO-Trial. Precise Neoadjuvant Chemoresection of Low-grade NMIBC Guided by Drug Sceens in Patient-derived Or-ganoids. An Open-label, Phase II Trial.
- Sponsor: Hospital Centre Biel/Bienne
- Enrolled: 28

## Sources

- ClinicalTrials.gov NCT06227065: https://clinicaltrials.gov/study/NCT06227065

## Connected records

- cancers: [Non-muscle-invasive bladder cancer](https://onco.cc/cancers/non-muscle-invasive-bladder-cancer/)
- technologies: [Patient-derived organoids](https://onco.cc/technologies/organoids/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Epirubicin](https://onco.cc/drugs/epirubicin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/)

---
JSON: https://onco.cc/api/v1/entities/nct06227065.json